Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21
- J Med Chem. 2023 Feb 20. doi: 10.1021/acs.jmedchem.2c01933.
- 1. Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany.
- 2. Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
- 3. Nuvisan Innovation Campus Berlin, 13353 Berlin, Germany.
- 4. Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
- 5. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
USP21 belongs to the Ubiquitin-Specific Protease (USP) subfamily of deubiquitinating Enzymes (DUBs). Due to its relevance in tumor development and growth, USP21 has been reported as a promising novel therapeutic target for Cancer treatment. Herein, we present the discovery of the first highly potent and selective USP21 inhibitor. Following high-throughput screening and subsequent structure-based optimization, we identified BAY-805 to be a non-covalent inhibitor with low nanomolar affinity for USP21 and high selectivity over Other DUB targets as well as kinases, proteases, and Other common off-targets. Furthermore, surface plasmon resonance (SPR) and cellular thermal shift assays (CETSA) demonstrated high-affinity target engagement of BAY-805, resulting in strong NF-κB activation in a cell-based reporter assay. To the best of our knowledge, BAY-805 is the first potent and selective USP21 inhibitor and represents a valuable high-quality in vitro chemical probe to further explore the complex biology of USP21.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: DeubiquitinaseResearch Areas: Cancer
-
target: DeubiquitinaseResearch Areas: Cancer